The Pharmacovigilance M&A Market
The global pharmacovigilance (PV) or drug safety market is projected to grow from $8.6bn in 2024 to $22.4bn by 2032.
Fundamental drivers shaping this growth include:
- Growing levels of drug consumption with increasing complexity of drugs being developed
- Increasingly stringent regulatory mandates and complex compliance requirements
- Technological advancements driving efficiencies in the PV market
- Continued trend of outsourcing in the pharma services industry, including of PV services
Anticipating an exciting growth outlook, the demand for pharmacovigilance (PV) is poised to fuel increased M&A activity.
To learn more about the key M&A trends taking shape this year in the pharmacovigilance space, read our latest paper.
If you would like to know more about the PV M&A landscape after reading this paper, or have any other questions on the wider pharmaceutical outsourcing space, please do get in touch - asultan@alvarezandmarsal.com.We would be delighted to discuss this report with you, including any implications these current and longer-term market themes may have on your business and overall shareholder objectives.
